Daniel K Nomura Selected Research

Monoacylglycerol Lipases

7/2015	Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer.
1/2015	Monoacylglycerol Lipase Regulates Fever Response.
10/2014	Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.
1/2014	Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome.
9/2011	Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice.
7/2011	Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer.
1/2010	Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis.
9/2008	Organophosphate-sensitive lipases modulate brain lysophospholipids, ether lipids and endocannabinoids.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel K Nomura Research Topics

Disease

40	Neoplasms (Cancer) 01/2022 - 09/2006
12	Breast Neoplasms (Breast Cancer) 01/2021 - 07/2014
8	Inflammation (Inflammations) 01/2021 - 12/2012
5	Triple Negative Breast Neoplasms 01/2021 - 01/2016
5	Obesity 12/2018 - 09/2008
4	Insulin Resistance 01/2020 - 01/2011
4	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 04/2011
4	Pain (Aches) 10/2014 - 09/2008
3	Glucose Intolerance 07/2017 - 01/2011
2	Melanoma (Melanoma, Malignant) 10/2021 - 07/2015
2	Fatty Liver 01/2020 - 02/2017
2	Infections 11/2019 - 01/2016
2	Carcinoma (Carcinomatosis) 01/2018 - 01/2018
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/2013 - 10/2011
2	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2013 - 11/2011
2	Neuroinflammatory Diseases 06/2012 - 11/2011
2	Catalepsy 07/2011 - 12/2009
1	Cystic Fibrosis (Mucoviscidosis) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Ketosis 01/2022
1	COVID-19 01/2021
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020
1	Leukemia 01/2020
1	Alcoholic Fatty Liver 01/2020
1	Spotted Fever Group Rickettsiosis (Rickettsialpox) 11/2019

Drug/Important Bio-Agent (IBA)

21	LipidsIBA 01/2021 - 01/2010
18	EnzymesIBA 01/2018 - 12/2009
14	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2006
12	EndocannabinoidsIBA 01/2016 - 09/2008
11	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 01/2010
8	Monoacylglycerol LipasesIBA 07/2015 - 09/2008
7	Ether (Diethyl Ether)IBA 02/2019 - 04/2008
6	Cysteine (L-Cysteine)FDA Link 01/2019 - 01/2017
6	Serine (L-Serine)FDA Link 01/2017 - 09/2006
6	EicosanoidsIBA 01/2016 - 06/2012
5	Pharmaceutical PreparationsIBA 01/2022 - 09/2011
5	Biological ProductsIBA 01/2019 - 01/2017
5	HydrolasesIBA 01/2017 - 09/2006
5	Cannabinoid Receptors (Cannabinoid Receptor)IBA 03/2013 - 09/2008
4	Amino Acids FDA Link 12/2018 - 01/2011
4	LigandsIBA 01/2018 - 01/2017
4	Platelet Activating FactorIBA 07/2015 - 09/2008
3	Phosphotransferases (Kinase)IBA 01/2022 - 01/2020
3	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2017
3	Triglycerides (Triacylglycerol)IBA 01/2018 - 01/2011
3	CytokinesIBA 01/2016 - 09/2011
3	Glycerophospholipids (Phosphoglycerides)IBA 11/2015 - 09/2013
3	Dronabinol (THC)FDA LinkGeneric 10/2014 - 09/2011
3	JZL 184IBA 01/2014 - 09/2011
2	Small Interfering RNA (siRNA)IBA 10/2021 - 04/2011
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 12/2012
2	Glutamic Acid (Glutamate)FDA Link 01/2021 - 12/2018
2	nimbolideIBA 01/2020 - 01/2019
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020 - 02/2019
2	NeuropeptidesIBA 01/2020 - 01/2018
2	SphingolipidsIBA 01/2020 - 10/2013
2	Terpenes (Terpenoids)IBA 11/2019 - 01/2019
2	Glutathione (Reduced Glutathione)IBA 11/2019 - 01/2017
2	Phosphates (Orthophosphate)IBA 02/2019 - 11/2015
2	LipopolysaccharidesIBA 12/2018 - 01/2015
2	LeptinIBA 01/2018 - 12/2014
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2017 - 06/2014
2	Estrogen ReceptorsIBA 01/2017 - 01/2016
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2017 - 01/2016
2	DiglyceridesIBA 01/2017 - 07/2015
2	Transcription Factors (Transcription Factor)IBA 01/2016 - 01/2016
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 07/2015 - 07/2015
2	Cyclooxygenase InhibitorsIBA 01/2015 - 09/2011
2	ProstaglandinsIBA 01/2015 - 11/2011
2	CannabinoidsIBA 03/2013 - 01/2011
2	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 07/2011 - 09/2008
1	lumacaftorIBA 01/2022
1	Chloride Channels (Chloride Channel)IBA 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021
1	LimoninsIBA 10/2021
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	remdesivirIBA 01/2021
1	PolyketidesIBA 11/2020
1	manumycinIBA 11/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 11/2020
1	CholesterolIBA 01/2020
1	Dasatinib (BMS 354825)FDA Link 01/2020
1	snake venom protein C activatorIBA 01/2020
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2020
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2020
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2020
1	Adenosine (Adenocard)FDA LinkGeneric 01/2020
1	IronIBA 11/2019
1	Cadherins (E-Cadherin)IBA 02/2019
1	Focal Adhesion Kinase 1IBA 01/2019
1	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2019
1	parthenolideIBA 01/2019
1	Therapeutic UsesIBA 01/2019
1	SesquiterpenesIBA 01/2019
1	methylene-lactoneIBA 01/2019
1	LactonesIBA 01/2019

Therapy/Procedure

18	Therapeutics 01/2021 - 09/2008
1	Ketogenic Diet 01/2022